Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.